Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study ; volume:13 ; number:1 ; day:11 ; month:11 ; year:2023 ; pages:1-9 ; date:12.2023
Scientific reports ; 13, Heft 1 (11.11.2023), 1-9, 12.2023
- Creator
-
Congdon, Seth
Narrowe, Zev
Yone, Nang
Gunn, Jacob
Deng, Yuting
Nori, Priya
Cowman, Kelsie
Islam, Marjan
Rikin, Sharon
Starrels, Joanna
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-46912-4
- URN
-
urn:nbn:de:101:1-2024013013064296318511
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Congdon, Seth
- Narrowe, Zev
- Yone, Nang
- Gunn, Jacob
- Deng, Yuting
- Nori, Priya
- Cowman, Kelsie
- Islam, Marjan
- Rikin, Sharon
- Starrels, Joanna
- SpringerLink (Online service)
Other Objects (12)
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia
Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia
Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia
Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients